NMD4C Launch Third Annual Training Series for Clinical Neuromuscular Fellows

The NMD4C Clinical Research Curriculum Development team is pleased to share that the third annual National Neuromuscular Lecture Series began this past August.

 

The NNLS is a year-long educational curriculum that provides training for clinical fellows enrolled in a Canadian neuromuscular fellowship program. The curriculum provides lectures from national experts in 32 key neuromuscular topics, developed in consultation with the directors of fellowship programs across Canada. The lecture series is designed to offer neuromuscular fellows at Canadian institutions the chance to learn from experts in different disciplines of neuromuscular medicine and forge connections with senior clinicians and investigators from across the country. The NNLS is approved by the Royal College of Physicians and Surgeons as a group learning activity as defined by the Maintenance of Certification Program, and fellows who attend over 75% of the lectures receive a certificate of attendance from the NMD4C.

 

In addition to lectures, this year’s program will also offer further engagement opportunities for participants as we introduce novel sessions in the form of journal club discussions, case presentations, and debates on emerging topics in neuromuscular medicine. The NNLS also offers opportunities for former fellows to stay involved in educational initiatives, and we are pleased to welcome Drs. Marianne Nury, Alasdair Rathbone, Issa Alawneh, Amanda Yaworski, Mona Hnaini, and Djurdja Djordjevic as moderators for this year’s program! They are joined by senior clinicians Drs. Alberto Aleman, Hernan Gonorazky, Erin O’Ferrall, Shahin Khayambashi and Jessica Theriault.

 

To learn more about the lecture series, please contact NNLS lead Dr. Alberto Aleman, or NDM4C Training and Curriculum coordinator Victoria Larocca.

NMD4C launches 2024-2025 NNLS

Read next...

Hope On The Horizon: Trials Treatments and Therapies for DMD, DM1 and MG

Hope on the Horizon: Trials, Treatments and Therapies for DMD, DM1 & MG

Nov 25-28, 2025 | Join us at Hope on the Horizon to learn more about the treatment and clinical trial landscape for Duchenne Muscular Dystrophy, Myotonic Dystrophy Type 1 and Myasthenia Gravis from key experts in the field!

Website - 2026 NMD4C Awards Now Open

2026 Awards Now Open for Nominations!

We’re proud to recognize outstanding achievements across the neuromuscular research community with our Three awards: Publication of the Year, Early Career Biomedical/Clinical Researchers of the Year.

AGAMREE (vamorolone) Approved treatment for DMD in Canada

A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada

Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.